Date of event
Wednesday, January 20, 2021 - 10:00 am -
Wednesday, January 20, 2021 - 11:00 am
Continuing Education Credits
None
Add to Calendar 2021-01-20 10:00:00 2021-01-20 11:00:00 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy AASLD alonzo.tolver@boldrstrategy.com America/New_York public

Content Contributor

Hepatitis B SIG

Presenters

Wen-Juei Jeng, MD
Harry Janssen, MD, PhD, FAASLD

Moderators

Marc Ghany, MD, FAASLD
Yao-Chun Hsu, MD, MSc, PhD

Details

This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended. We will conclude with a twenty-minute discussion on the gaps in current knowledge, whether and how the practice can be individualized.

Sponsor

AASLD is grateful to AbbVie for its generous sponsorship of AASLD Webinars

Presenter Bios

Wen-Juei Jeng, MD

Rachel Wen-Juei Jeng, MD received her Doctor of Medicine Education from College of Medicine, National Yang-Ming University, Taiwan (1998-2005). She has accomplished internal medicine residency, Gastroenterology fellowship training and becomes a faculty and physician scientist in Department of Gastroenterology and Hepatology in Chang Gung Memorial Hospital, Linkou branch, Taiwan. She currently serves as an Associate Professor in College of Medicine, Chang Gung University since 2019.

Dr. Jeng’s research interests mainly focus on viral hepatitis (esp. HBV) and clinical hepatology. She has been working with her mentor Prof. Yun-Fan Liaw and published a series of off-Nuc therapy cohort study in Hepatology and Clinical Gastroenterology and Hepatology. She now serves as a member of TASL, EASL and AASLD.

Photo of Wen-Juei Jeng, MD


 

Harry Janssen, MD, PhD, FAASLD

Harry L. A. Janssen, MD, PhD, FAASLD is a professor of medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in Hepatology. He currently works at Toronto General Hospital as Chief of Hepatology and Director of the Toronto Centre for Liver Disease, the largest Liver Clinic in North America.

Professor Janssen graduated from medical school in Nijmegen, The Netherlands. During his study he spent one year as research fellow in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in chronic hepatitis B. Following his training in Internal Medicine in Leiden and Gastroenterology at the Erasmus University in Rotterdam, he returned to the Mayo Clinic for a Research Fellowship in Hepatology at the Center of Basic Research in Digestive Diseases. In 2001 he became a faculty member and in 2006 he was appointed as full Professor of Hepatology at the Erasmus University and Chief of the Section Liver Diseases and Transplantation at the ErasmusMC in Rotterdam. In 2013 he moved to Canada to head the Liver Program at Toronto Western Hospital. In 2016 he merged all three Toronto Liver Programs into the Toronto Centre for Liver Disease, based at Toronto General Hospital, University Health Network.

Professor Janssen has coordinated numerous European and global multicenter studies on the natural history and treatment for chronic viral hepatitis and other liver diseases. He has published more than 470 original peer-reviewed papers and many book chapters. His H-index is 87 (Google Scholar). He has acquired $ 50 million USD in research funding from many different organizations among which NIH, European Commission, CIHR and NWO. He has received several prestigious international awards and has mentored over 50 PhD students, many of whom have taken leadership positions in the field of Hepatology or Virology. In addition to his longstanding expertise in antiviral therapy of chronic viral hepatitis, he is a leading scientist in the field of vascular disorders of the liver. Professor Janssen is a member of the EASL Guideline Committees for both Hepatitis B and for Vascular Liver Disease. He currently serves as the Vice Chair of the AASLD Special Interest Group (SIG) for Hepatitis B and he is the Global Chair of the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD).

Photo of Harry Janssen, MD, PhD, FAASLD

Moderator Bios

Marc Ghany, MD, FAASLD

Marc G. Ghany, MD, MHSc, FAASLD is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis.

Photo of Marc Ghany, MD, FAASLD


 

Yao-Chun Hsu, MD, MSc, PhD

Yao-Chun Hsu, MD, MSc, PhD is currently the director of the Center for Liver Diseases in the E-Da Hospital and associate professor of the School of Medicine in the I-Shou University, both located in Kaohsiung, Taiwan. He graduated with honor from the National Taiwan University (NTU) School of Medicine in 2002, and then completed medical training in internal as well digestive medicine in the NTU Hospital in 2007. He received academic training and earned his MSc and PhD degrees in 2009 and 2014, respectively.

Dr. Hsu, a physician scientist, devotes himself to clinical and translational investigation in gastroenterology and hepatology, with a particular focus on chronic viral hepatitis and complications of advanced liver diseases. He is active in academic publishing with research works published in prestigious journals such as HEPATOLOGY, Journal of Hepatology and Gut. Since 2018, he has served as associate editor (in liver section) for Digestive Diseases.

Photo of Yao-Chun Hsu, MD, MSc, PhD